Guggenheim Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Guggenheim raised Merck’s price target to $146 from $145 and maintained a “buy” rating, implying 13.81% upside from the previous close. Analysts collectively give the stock a “Moderate Buy” rating with an average target of $134.56.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while its adjusted loss of $0.13 per share was better than expected. Keytruda and newer products drove the revenue growth.
• Merck narrowed its 2026 revenue outlook but cut EPS guidance to $2.66–$2.76, pressured by acquisition-related charges. Institutional investors own approximately 76.07% of the company’s shares.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target upped by stock analysts at Guggenheim from $145.00 to $146.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price objective suggests a potential upside of 13.81% from the stock's previous close.

MRK has been the subject of a number of other research reports. Cantor Fitzgerald reissued a "neutral" rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Barclays upped their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, July 13th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price for the company. Thirteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $134.56.

Merck & Co., Inc. Trading Up 0.4%

NYSE:MRK opened at $128.28 on Wednesday. The stock has a market cap of $316.83 billion, a PE ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock's 50-day moving average is $123.45 and its two-hundred day moving average is $118.78.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. During the same period last year, the company posted $2.13 earnings per share. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Institutional Trading of Merck & Co., Inc.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $3,997,933,000. Wellington Management Group LLP grew its holdings in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. bought a new position in Merck & Co., Inc. during the 4th quarter valued at about $1,012,530,000. Jennison Associates LLC bought a new stake in Merck & Co., Inc. during the fourth quarter worth about $585,192,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company's stock worth $1,973,983,000 after acquiring an additional 5,152,069 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above analysts’ $16.37 billion estimate and up 5.1% year over year. Adjusted EPS was a loss of $0.13, but this was better than the expected loss of $0.26. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda and newer products drove the beat. Keytruda remained the key growth engine, while the injectable version reportedly exceeded Wall Street’s sales forecast by more than $200 million. Strength in oncology and recently launched products supported the improved outlook. The Merck Product That Absolutely Demolished Wall Street's Forecasts
• Positive Sentiment: Merck raised and narrowed its 2026 revenue guidance to approximately $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion consensus estimate. The revision signals confidence in demand for its oncology portfolio and newer medicines. Merck hikes revenue outlook as new drug sales grow
• Neutral Sentiment: Management highlighted additional regulatory, clinical and pipeline milestones, including updates to its HIV program. These developments may support longer-term growth, but they do not materially change current-year earnings expectations. Merck Announces Second-Quarter 2026 Financial Results
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, far below the prior analyst consensus of $3.42. Acquisition-related charges from the Terns deal are weighing on reported profits, and the company’s quarterly loss compares with $2.13 EPS in the year-ago period. Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source